The FDA declined to approve one of biotech’s most closely watched cancer drugs
The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.
Read original reporting ↗Business
The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.
Read the original report, then compare company disclosures and the relevant official data. A headline alone does not establish an effect on markets.
The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.
Read original reporting ↗No additional matched coverage has been archived for this story yet.
This page preserves an attributed headline and brief excerpt. The publisher maintains the original report and any subsequent corrections. Report a classification or link issue →